INOVIQ Limited (ASX:IIQ) Advances Exosome Therapy for Breast Cancer
Successful Development Milestone
INOVIQ Limited (ASX: IIQ) has successfully completed stage 1 of its development program for an exosome therapeutic for breast cancer treatment. The company reports that its proof-of-concept study demonstrated that engineered natural killer (NK) cells can produce exosomes that target and kill breast cancer cells.
Therapeutic Efficacy and Future Steps
The study achieved specific targeting through a chimeric antigen receptor (CAR) incorporated into the exosome surface, leading to notable efficacy against triple-negative breast cancer cells. Treatment resulted in over 30% cancer cell death at the highest evaluated dose. INOVIQ is now focused on optimising dosing and enhancing anti-tumour activity through further treatment of animal models, anticipating future in vitro data in the first half of CY25 and in vivo efficacy data in the second half of CY25.
Executive Comments
Chief Scientific Officer, Prof Gregory Rice, commented on the progress, stating, “INOVIQ’s team has delivered significant progress in the complex task of successfully developing a robust and reproducible CAR-exosome production process.” He expressed confidence in further enhancing the therapeutic efficacy. CEO Dr Leearne Hinch added, “We are thrilled by these POC results that show the potential of our exosome program to provide a life-saving breast cancer therapeutic for patients.” Future studies will propel the company towards clinical trials, with ongoing collaboration with regulatory consultants to refine development strategies.
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.